Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duesseldorf – page 69

2 009 clinical trials in Duesseldorf, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duesseldorf at a glance
2 009
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

2 009 trials in Duesseldorf

Open in trial search

Study of Benfooxythiamine Monosodium Added to Lutetium‑177 Vipivotide Tetraxetan in Adults with Metastatic Castration‑Resistant Prostate Cancer and Stable Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Benfovir AG

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Bisirna Therapeutics Pte. Ltd.

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Type 2 diabetes mellitus

Not yet recruiting

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Albiglutide
  • Sponsor:Eli Lilly & Co.

Chronic lymphocytic leukaemia+2

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Tislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AIO-Studien gGmbH

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not yet recruiting

Optimizing biologic tapering in patients with rheumatoid arthritis using tocilizumab, drug combination, and olfactory placebo conditioning

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Universiteit Leiden

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duesseldorf

What the registry says about research in the country

01 Oncology and Hematologic Malignancies

In Düsseldorf, a large share of trials focuses on cancer research and blood cancers, with studies in breast cancer, colorectal cancer, prostate cancer, multiple myeloma, and leukemia. These trials are mainly testing new treatment combinations, improving post-surgery care, and exploring ways to delay or prevent recurrence.

  • Breast cancer and triple-negative breast cancer research
  • Colorectal cancer, prostate cancer, and other solid tumors
  • Multiple myeloma, lymphoma, AML, and MDS
  • Testing new therapy strategies and improving treatment outcomes

This field is especially active across the city’s research sites, reflecting a strong interest in both common and hard-to-treat malignancies.

02 Dermatology and Hair Disorders

Another important area is skin and connective tissue disease research, including studies on psoriasis, actinic keratosis, androgenetic alopecia, and facial line treatments. These trials are mainly aimed at evaluating new topical or injectable therapies and improving visible symptom control.

  • Moderate to severe plaque psoriasis
  • Actinic keratosis of the face or scalp
  • Androgenetic alopecia in men and women
  • Facial line and cosmetic treatment studies

Several of these studies are designed to compare active treatment with control care and help refine everyday dermatologic treatment options.

03 Digestive and Liver Diseases

Trials in digestive system diseases and virus diseases include research on chronic hepatitis D, metabolic dysfunction-associated steatotic liver disease, and advanced cancers involving the pancreas, colon, and bile ducts. The main goal is to improve treatment effectiveness and support better disease control in difficult liver and gastrointestinal conditions.

  • Chronic hepatitis D infection
  • Metabolic dysfunction-associated steatotic liver disease
  • Pancreatic, colon, and cholangiocarcinoma studies
  • Testing new therapies and surgery-related strategies

These studies highlight a strong focus on therapies for chronic liver illness and advanced abdominal cancers.

04 Neurology and Multiple Sclerosis

Research in nervous system diseases includes trials for multiple sclerosis and other neurological conditions, with an emphasis on long-term safety and treatment benefit. In Düsseldorf, these studies are helping assess whether newer immune-based approaches can better support patients over time.

  • Relapsing multiple sclerosis
  • Progressive multiple sclerosis
  • Broader nervous system disease research
  • Evaluating treatment safety and durability

This area reflects ongoing interest in therapies that may offer steadier disease control with acceptable tolerability.

05 Pediatric and Adolescent Conditions

Pediatric trials cover serious conditions such as high-risk neuroblastoma, acute lymphoblastic leukemia, and respiratory distress in preterm infants. These studies aim to improve survival, reduce complications, and support better long-term outcomes in children and young people.

  • High-risk neuroblastoma
  • Ph+ and ABL-class B-cell acute lymphoblastic leukemia
  • Respiratory distress syndrome in preterm infants
  • Testing more effective treatment and prevention approaches

These trials bring together cancer care and neonatal research, showing a wide pediatric research footprint in the city.

06 Hematology and Bone Marrow Disorders

Several studies address hemic and lymphatic diseases, especially myelodysplastic syndromes, anemia, and refractory hematologic malignancies. The purpose is to find better ways to restore blood counts, improve transfusion independence, and treat patients whose disease has returned or no longer responds to standard therapy.

  • Lower-risk myelodysplastic syndromes
  • Anemia linked to marrow disorders
  • Relapsed or refractory mantle cell lymphoma
  • Evaluating new blood cancer treatments

This research area is particularly important for patients with limited treatment options and persistent blood-related symptoms.

07 Endocrine and Metabolic Research

Düsseldorf also hosts trials in hormonal diseases and nutritional and metabolic diseases, including work on hair loss linked to hormonal imbalance and liver-related metabolic disorders. These studies are designed to test treatment effectiveness and improve symptom management in conditions that often affect quality of life.

  • Hormone-related hair loss
  • Metabolic liver disease
  • Treatment studies in endocrine and metabolic care
  • Assessing benefit and safety of newer therapies

These trials connect chronic metabolic care with visible, patient-centered outcomes.

08 Immunology and Infectious Disease-Related Research

The city’s trial portfolio includes immune system disease research and studies linked to virus diseases, especially where immune pathways affect chronic illness or cancer care. Researchers are exploring new treatment options that may improve control of persistent viral infection and immune-driven disease.

  • Chronic hepatitis D
  • Immune-related treatment strategies
  • Conditions involving chronic inflammation and infection
  • Evaluating newer immune-targeted therapies

This work shows how immunology and virology often overlap in modern clinical research.

09 Diagnostic Imaging and Research Tools

A smaller but important part of the research landscape involves diagnostic techniques and equipment, including studies that assess how well advanced imaging can identify disease and guide care. These trials are focused on improving diagnosis and helping clinicians distinguish between disease subtypes more accurately.

  • Prostate cancer imaging and diagnosis
  • Evaluating PET-based diagnostic performance
  • Improving disease classification
  • Supporting earlier and more precise diagnosis

In Düsseldorf, diagnostic research complements the treatment studies by strengthening the tools used to identify and monitor disease.

10 Respiratory and Early-Life Health

Trials in respiratory tract diseases include research aimed at improving outcomes for preterm infants with breathing problems early in life. The focus is on prevention and better long-term lung function, with the goal of reducing complications that can affect childhood development.

  • Respiratory distress syndrome in premature babies
  • Early intervention and prevention strategies
  • Long-term lung health
  • Supporting better outcomes in neonatal care

This area links specialized newborn care with research designed to improve later respiratory health.

11 Broad Experimental and Translational Studies

Some trials in Düsseldorf span advanced solid tumors and other difficult-to-treat conditions, reflecting a broad translational research effort. These studies are often designed to test whether new therapies can produce meaningful disease control in patients with limited standard options.

  • Advanced solid tumors
  • Mixed oncology populations
  • Early evaluation of promising therapies
  • Exploring anti-tumor activity and safety

This part of the research landscape supports the development of new approaches across multiple cancer types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.